Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

François-Xavier Mahon

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Best Practice & Research. Clinical Haematology|November 15, 2016
Discontinuation of TKI therapy and 'functional' cure for CMLFrançois-Xavier Mahon
Oncogene|July 12, 2005
JAK the triggerFrançois-Xavier Mahon
Best Practice & Research. Clinical Haematology|December 5, 2009
Pharmacologic monitoring and determinants of intracytoplasmic drug levelsFrançois-Xavier Mahon
La Revue Du Praticien|December 13, 2005
[Leucemogenesis of chronic myelogenous leukemia]François-Xavier Mahon
Hematology. American Society of Hematology. Education Program|December 13, 2012
Is going for cure in chronic myeloid leukemia possible and justifiable?François-Xavier Mahon
British Journal of Haematology|October 20, 2017
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapyDelphine Rea, François-Xavier Mahon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Deep molecular response in chronic myeloid leukemia: the new goal of therapy?François-Xavier Mahon, Gabriel Etienne
Medecine Sciences : M/S|December 8, 2004
[Origin of resistance to Imatinib mesylate: lessons learned from this experience]Catherine Roche-Lestienne, François-Xavier Mahon, Claude Preudhomme
Leukemia Research|September 10, 2017
A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell lineKelly Airiau, Béatrice Turcq, François-Xavier Mahon, et al.
Current Hematologic Malignancy Reports|March 14, 2012
Curing chronic myeloid leukemiaDelphine Rea, Philippe Rousselot, Joelle Guilhot, et al.
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Best Practice & Research. Clinical Haematology|November 15, 2016
Discontinuation of TKI therapy and 'functional' cure for CMLFrançois-Xavier Mahon
Oncogene|July 12, 2005
JAK the triggerFrançois-Xavier Mahon
Best Practice & Research. Clinical Haematology|December 5, 2009
Pharmacologic monitoring and determinants of intracytoplasmic drug levelsFrançois-Xavier Mahon
La Revue Du Praticien|December 13, 2005
[Leucemogenesis of chronic myelogenous leukemia]François-Xavier Mahon
Hematology. American Society of Hematology. Education Program|December 13, 2012
Is going for cure in chronic myeloid leukemia possible and justifiable?François-Xavier Mahon
British Journal of Haematology|October 20, 2017
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapyDelphine Rea, François-Xavier Mahon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Deep molecular response in chronic myeloid leukemia: the new goal of therapy?François-Xavier Mahon, Gabriel Etienne
Medecine Sciences : M/S|December 8, 2004
[Origin of resistance to Imatinib mesylate: lessons learned from this experience]Catherine Roche-Lestienne, François-Xavier Mahon, Claude Preudhomme
Leukemia Research|September 10, 2017
A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell lineKelly Airiau, Béatrice Turcq, François-Xavier Mahon, et al.
Current Hematologic Malignancy Reports|March 14, 2012
Curing chronic myeloid leukemiaDelphine Rea, Philippe Rousselot, Joelle Guilhot, et al.
Pageof 12